【藥品性質提示】 根據 2019 AGS Beers Criteria，本藥品為【潛在不適當用藥 (PIM)】，不建議用於治療老年人高血壓。 #特殊劑型：不建議磨粉、管灌藥品

高血壓 (Alpha-blocker) Benign prostatic hyperplasia, hypertension

Doxazosin mesylate, a quinazoline compound, selectively inhibits the alpha(1)-subtype of alpha adrenergic receptors, and binds highly to alpha(1A) adrenoceptor. Alpha1 receptor blockade decreases urethral resistance and may relieve symptoms of benign prostatic hyperplasia and increase urine flow. The antihypertensive effect of doxazosin is attributed to a decrease in systemic vascular resistance.

Tmax: 8 to 9 hours; Bioavailability, Oral: 54% to 59% of immediate-release; Effect of food: Increases Cmax by 32% and AUC by 18%; Protein binding: 98%; Metabolism -Hepatic: Extensive, CYP3A4 (primary), CYP2D6 and CYP2C19, O-demethylation and hydroxylation. Excretion- Fecal: approximately 63%, 4.8% unchanged; Renal: 9%, trace unchanged; Dialyzable: No (hemodialysis). Elimination Half Life: 15 to 19 hours

Hypersensitivity to quinazolines such as prazosin and terazosin

C/B in conflict

Infant risk cannot be ruled out.[MDX]; In animal model, it can be concentrated in milk up to 20 times the serum level.

Orthostatic hypotension, dizziness, vertigo, and headaches are the most common adverse effects.

Benign prostatic hyperplasia: initial, 4 mg PO QD with breakfast; may titrate if necessary at 3- to 4-week intervals to 4 to 8 mg PO QD, MAX 8 mg/day

No dosing adjustments are required in renal failure patients.

Hepatic impairment (severe, Child-Pugh C): Use not recommended